K
Karla Plevová
Researcher at Central European Institute of Technology
Publications - 98
Citations - 2734
Karla Plevová is an academic researcher from Central European Institute of Technology. The author has contributed to research in topics: Chronic lymphocytic leukemia & IGHV@. The author has an hindex of 23, co-authored 84 publications receiving 2098 citations. Previous affiliations of Karla Plevová include Masaryk University.
Papers
More filters
Journal ArticleDOI
Towards error-free profiling of immune repertoires
Mikhail Shugay,Olga V. Britanova,Ekaterina M. Merzlyak,Maria A. Turchaninova,Ilgar Z. Mamedov,Timur R Tuganbaev,Dmitriy A. Bolotin,Dmitry B. Staroverov,Ekaterina V. Putintseva,Karla Plevová,Carsten Linnemann,Dmitriy A. Shagin,Šárka Pospíšilová,Sergey Lukyanov,Sergey Lukyanov,Ton N. Schumacher,Dmitriy M. Chudakov +16 more
TL;DR: MIGEC (molecular identifier groups–based error correction), a strategy for high-throughput sequencing data analysis, allows for nearly absolute error correction while fully preserving the natural diversity of complex immune repertoires.
Journal ArticleDOI
High-quality full-length immunoglobulin profiling with unique molecular barcoding.
Maria A. Turchaninova,Maria A. Turchaninova,Maria A. Turchaninova,Alexey N. Davydov,Olga V. Britanova,Olga V. Britanova,Mikhail Shugay,Mikhail Shugay,Vasileios Bikos,Evgeny S. Egorov,Evgeny S. Egorov,Evgeny S. Egorov,V. I. Kirgizova,Ekaterina M. Merzlyak,Dmitry B. Staroverov,Dmitry B. Staroverov,Dmitriy A. Bolotin,Dmitriy A. Bolotin,Ilgar Z. Mamedov,Ilgar Z. Mamedov,Mark Izraelson,Mark Izraelson,Mark Izraelson,Maria D. Logacheva,O. Kladova,Karla Plevová,Šárka Pospíšilová,Dmitriy M. Chudakov,Dmitriy M. Chudakov,Dmitriy M. Chudakov +29 more
TL;DR: A robust protocol for the full-length profiling of human and mouse IG repertoires using unique molecular identifiers introduced in the course of cDNA synthesis to control bottlenecks and to eliminate PCR and sequencing errors is presented.
Journal ArticleDOI
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.
Jitka Malčíková,Katerina Stano-Kozubik,Boris Tichy,Barbara Kantorová,Šárka Pavlová,Nikola Tom,Lenka Radová,Jana Šmardová,Filip Pardy,Michael Doubek,Yvona Brychtová,Marek Mráz,Karla Plevová,Eva Divíšková,Alexandra Oltová,Jiří Mayer,Šárka Pospíšilová,Martin Trbušek +17 more
TL;DR: Patients with minor-clone TP53 mutations carry a high risk of mutation selection by therapy, and deep sequencing can shift TP53 mutation identification to a period before therapy administration, which might be of particular importance for clinical trials.
Journal ArticleDOI
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
Viktor Ljungström,Diego Cortese,Emma Young,Tatjana Pandzic,Larry Mansouri,Karla Plevová,Stavroula Ntoufa,Panagiotis Baliakas,R Clifford,Lesley-Ann Sutton,Stuart Blakemore,Niki Stavroyianni,Andreas Agathangelidis,Davide Rossi,Martin Höglund,Jana Kotašková,Gunnar Juliusson,Chrysoula Belessi,Nicholas Chiorazzi,Panagiotis Panagiotidis,Anton W. Langerak,Karin E. Smedby,David Oscier,Gianluca Gaidano,Anna Schuh,Frederic Davi,Christiane Pott,Jonathan C. Strefford,Livio Trentin,Šárka Pospíšilová,Paolo Ghia,Kostas Stamatopoulos,Tobias Sjöblom,Richard Rosenquist +33 more
TL;DR: Novel insights are provided into the heterogeneous genetic landscape of CLL relapsing after FCR treatment and a novel mechanism underlying clinical aggressiveness involving a mutated ribosomal protein is highlighted, potentially representing an early genetic lesion in CLL pathobiology.
Journal ArticleDOI
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact
Panagiotis Baliakas,Sabine Jeromin,Michalis Iskas,Anna Puiggros,Karla Plevová,Karla Plevová,Florence Nguyen-Khac,Zadie Davis,Gian Matteo Rigolin,Andrea Visentin,Aliki Xochelli,Julio Delgado,Fanny Baran-Marszak,Evangelia Stalika,Pau Abrisqueta,Kristina Durechova,George Papaioannou,Virginie Eclache,Maria Dimou,Theodoros Iliakis,Rosa Collado,Michael Doubek,Michael Doubek,M. Jose Calasanz,Neus Ruiz-Xivillé,Carolina Moreno,Marie Jarošová,Marie Jarošová,Alexander C. Leeksma,Panayiotis Panayiotidis,Helena Podgornik,Florence Cymbalista,Achilles Anagnostopoulos,Livio Trentin,Niki Stavroyianni,Fred Davi,Paolo Ghia,Arnon P. Kater,Antonio Cuneo,Šárka Pospíšilová,Šárka Pospíšilová,Blanca Espinet,Anastasia Athanasiadou,David Oscier,Claudia Haferlach,Kostas Stamatopoulos +45 more
TL;DR: A novel hierarchical model is proposed in which patients with high-CK exhibit the worst prognosis, whereas those with mutated CLL lacking CK or TP53abs, as well as CK with +12,+19, show the longest overall survival.